NewAmsterdam Pharma Company N.V.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $430.1M | — |
| FY2023 | — | $288.4M | $340.5M |
| FY2024 | — | $757.5M | $771.7M |
| FY2025 | — | $683.4M | $490.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $430.1M | — |
| FY2023 | — | $288.4M | $340.5M |
| FY2024 | — | $757.5M | $771.7M |
| FY2025 | — | $683.4M | $490.0M |